ReNewVax is pioneering a new approach to vaccine development, focused on tackling some of the world’s most urgent bacterial disease challenges. As antimicrobial resistance continues to rise and existing vaccines struggle to keep pace with evolving pathogens, ReNewVax is building a new generation of broadly protective, cost-effective vaccines designed for global impact.
At the core of ReNewVax’s innovation is a genomics-driven, reverse vaccinology platform. By analysing large-scale clinical data, the company identifies conserved protein targets shared across all variants of a pathogen - enabling the development of vaccines that provide universal protection rather than targeting only a limited subset of strains.
The company’s lead programme, RVX-001, is designed to be the first universal vaccine against Streptococcus pneumoniae (pneumococcus), a major cause of pneumonia, meningitis, and sepsis worldwide. Unlike existing vaccines that cover only a fraction of known variants, RVX-001 aims to protect against all ~100 serotypes, addressing a critical gap in global healthcare.
ReNewVax is also advancing a broader pipeline targeting other high-priority bacterial threats, including Group B and Group A Streptococcus. Its approach combines scientific innovation with scalable, lower-cost manufacturing, helping expand access to life-saving vaccines across both high- and low-income regions.
Founded in 2022 as a spin-out from the University of Liverpool, ReNewVax brings together expertise in immunology, genomics, and translational research to accelerate vaccine development from discovery through to clinical application. ([University of Liverpool][4])
ReNewVax’s mission is to protect lives by delivering universal vaccines that reduce infection, lower antibiotic use, and play a critical role in the global fight against antimicrobial resistance.
Visit website